Abstract:
This invention provides compounds of formula (I): wherein R 1a , R 1 , R 2a , and R 2b have values as described in the specification, useful as inhibitors of HDAC6. The invention also provides pharmaceutical compositions comprising the compounds of the invention and methods of using the compositions in the treatment of proliferative, inflammatory, infectious, neurological or cardiovascular diseases or disorders.
Abstract:
This invention provides beta-carboline compounds of formula I: wherein R 1 , R 2 , R 3 , R 4 , R 5 , G, and x are as described in the specification. The compounds are useful for treating cancer and inflammatory disorders.
Abstract:
This invention provides compounds of formula (/): (Formula ( I ) wherein R 1 , R 1b , R 2a , R 2b , R 2c , and R 2d have values as described in the specification, useful as inhibitors of HDAC6. The invention also provides pharmaceutical compositions comprising the compounds of the invention and methods of using the compositions in the treatment of proliferative, inflammatory, infectious, neurological or cardiovascular diseases or disorders.
Abstract:
This invention provides compounds of formula ( I ) wherein ring A, X 1 , X 2 , X 3 , R 2 , R 4b , R 10 , and G have values as described in the specification, useful as inhibitors of HDAC6. The invention also provides pharmaceutical compositions comprising the compounds of the invention, and methods of using the compositions in the treatment of proliferative, inflammatory, infectious, neurological or cardiovascular diseases or disorders.
Abstract:
Disclosed herein are compounds represented by Structural Formula: (I) and (I-A). Also disclosed is the use of such compounds for inhibiting the G-protein coupled receptor referred to as chemoattractant receptor-homologous molecule expressed on Th2, or simply "CRTH2" for the treatment of inflammatory disorders. The variables in Structural Formula (I) and (I-A) are defined herein.
Abstract:
Disclosed herein are compounds represented by Structural Formula (I), wherein the variables are defined herein. Also disclosed is the use of such compounds for inhibiting the G-protein coupled receptor referred to as chemoattractant receptor-homologous molecule expressed on Th2 ("CRTH2") for the treatment of inflammatory disorders.
Abstract:
A system (110) for automatic categorization and assessment of billing narratives has a semantic engine (154) that classifies billing entries (152) with descriptions expressed in natural language into standardized categories of activity and task objective. The classification is by machine learning methods via training data (210) that is maintained, updated and extended as needed. A rules engine (162) applies rules to the categorized invoice data (160) to analyze the data, report violations to a user/consumer of billed services and to perform related calculations.
Abstract:
This invention provides compounds of formula (I): wherein R 1a , R 1b , R 1c , R 2a , R 2b , R 2c and R 2d have values as described in the specification, useful as inhibitors of HDAC6. The invention also provides pharmaceutical compositions comprising the compounds of the invention and methods of using the compositions in the treatment of proliferative, inflammatory, infectious, neurological or cardiovascular diseases or disorders.
Abstract:
Disclosed herein are compounds represented by Structural Formula (I), wherein the variables are defined herein. Also disclosed is the use of such compounds for inhibiting the G-protein coupled receptor referred to as chemoattractant receptor-homologous molecule expressed on Th2 ("CRTH2") for the treatment of inflammatory disorders.
Abstract:
Disclosed are CRTH2 inhibitors represented by Structural Formula (I). The values for the variables of Structural Formula (I) are provided herein.